Stockscreener 앱 받기
607.93
1.11%
-6.80
시간 외 거래:
606.99
-0.94
-0.15%
전일 마감가:
$614.73
열려 있는:
$615.16
하루 거래량:
1.30M
Relative Volume:
1.52
시가총액:
$63.73B
수익:
$14.92B
순이익/손실:
$4.42B
주가수익비율:
14.81
EPS:
41.0422
순현금흐름:
$3.79B
1주 성능:
+1.04%
1개월 성능:
-12.94%
6개월 성능:
-18.92%
1년 성능:
+19.47%
1일 변동 폭
$602.13
$620.00
1주일 범위
$602.13
$620.00
52주 변동 폭
$503.25
$821.11
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 재개 | Piper Sandler | Overweight |
| 2026-03-06 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Regeneron Pharmaceuticals Stock (US75811P1003): Analyst coverage and fundamentals in focus - AD HOC NEWS
Regeneron Pharma Stock (US75886F1075): Valuation In Focus After Recent Pullback - AD HOC NEWS
Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations - simplywall.st
(REGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Regeneron Broadens Pipeline With Ebola Antibody Trials And Bispecific Cancer Bets - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (REGN) Shareholder/Analyst CallSlideshow (NASDAQ:REGN) 2026-06-12 - Seeking Alpha
REGN: All board proposals passed as strong growth and pipeline advances were highlighted - TradingView
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Parabilis Medicines closes $770.5m IPO, Regeneron investment By Investing.com - Investing.com Canada
Regeneron backs Parabilis (PBLS) with IPO private placement and new charter - Stock Titan
Regeneron Pharmaceuticals, Inc. (REGN) stock price, news, quote and history - Yahoo Finance Singapore
Regeneron Keeps Biotech Execution In Focus Amid Market Volatility - Kalkine Media
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now? - Insider Monkey
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy - BioPharma Dive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Regeneron-backed Parabilis rises on market debut (REGN:NASDAQ) - Seeking Alpha
Parabilis Medicines Raises $670 Million in Initial Public Offering - Pharmaceutical Executive
How WHO’s Maftivimab Priority for Bundibugyo Trials At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak - Insider Monkey
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO - marketscreener.com
Parabilis Medicines (PBLS) launches IPO with $75M Regeneron private placement - Stock Titan
Allergic Rhinitis Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight - Barchart.com
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
5 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Daiwa Securities Group Inc. Sells 2,058 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court - Law360
Regeneron Pharmaceuticals Inc stock (US7739031091): valuation metrics in focus after recent trading - AD HOC NEWS
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein - The National Law Review
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Alvotech targets J&J’s Simponi and Regeneron’s Eylea (ALVO) - Seeking Alpha
Cambridge biotech plans $450M IPO with Regeneron backing - The Business Journals
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
With Strong Cash Flow, Regeneron Pharmaceuticals Stock Poised to Rise? - Trefis
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리제네론 파마슈티컬스 주식 (REGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RYAN ARTHUR F | Director |
Apr 01 '26 |
Sale |
777.27 |
100 |
77,727 |
17,603 |
| RYAN ARTHUR F | Director |
Mar 02 '26 |
Sale |
785.50 |
100 |
78,550 |
17,703 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Option Exercise |
376.69 |
1,638 |
617,018 |
3,341 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Sale |
781.33 |
1,638 |
1,279,812 |
1,703 |
1.57%
0.47%
자본화:
|
볼륨(24시간):